Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications
Aino Soro-Paavonen, Daniel Gordin, Carol Forsblom, Milla Rosengard-Barlund, Johan Waden, Lena Thorn, Niina Sandholm, Merlin C Thomas, Per-Henrik Groop
JOURNAL OF HYPERTENSION | LIPPINCOTT WILLIAMS & WILKINS | Published : 2012
OBJECTIVE: Angiotensin-converting enzyme 2 (ACE2) is a homolog of ACE that counterbalances the actions of angiotensin (AT)II and promotes vasodilatation. Circulating ACE2 activity is increased in diabetes in experimental models. The role of ACE2 in human pathophysiology is unknown. We examined whether ACE2 activity is altered in patients with type 1 diabetes (T1D), with and without diabetic nephropathy. METHODS: Quantitative ACE2 activity in serum was measured by a fluorometric assay in 859 patients with T1D in the Finnish Diabetic Nephropathy (FinnDiane) study and in 204 healthy controls. Pulse-wave analysis with augmentation index (AIx) measurement was performed in 319 patients with T1D an..View full abstract
This study was supported by Finnish Cultural Foundation, The Finnish Diabetes Research Foundation, Maud Kuistila Foundation and Folkhalsan Research Foundation.